Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...

Descrizione completa

Dettagli Bibliografici
Autori principali: Bhagirath B. Solanki, Christine Juergens, Manojkumar B. Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W. Cutler, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma
Natura: Articolo
Lingua:English
Pubblicazione: Taylor & Francis Group 2017-09-01
Serie:Human Vaccines & Immunotherapeutics
Soggetti:
adults
india
immunogenicity
safety
thirteen-valent pneumococcal conjugate vaccine
Accesso online:http://dx.doi.org/10.1080/21645515.2017.1331796

Accesso online

http://dx.doi.org/10.1080/21645515.2017.1331796

Documenti analoghi